Content about Migraine

May 21, 2013

Impax Labs has launched an authorized generic drug for migraine headaches under a partnership with AstraZeneca, Impax said.

HAYWARD, Calif. — Impax Labs has launched an authorized generic drug for migraine headaches under a partnership with AstraZeneca, Impax said.

Impax said its generics division, Global Pharmaceuticals, began shipping authorized generic zolmitriptan tablets and orally disintegrating tablets in the 2.5 mg and 5 mg strengths. The drug is a version of AstraZeneca's Zomig.

Zomig had sales of about $196 million during the 12-month period that ended in April, according to IMS Health.

May 15, 2013

The Food and Drug Administration has approved a generic migraine drug made by Mylan, the company said Wednesday.

PITTSBURGH — The Food and Drug Administration has approved a generic migraine drug made by Mylan, the company said Wednesday.

Mylan announced the approval of zolmitriptan tablets in the 2.5 mg and 5 mg strengths. The drug maker plans to launch the product immediately.

The drug is a generic version of IPR Pharmaceuticals' Zomig and is used for the acute treatment of migraine in adults. Various versions of the drug had sales of $152.8 million during the 12-month period that ended in March, according to IMS Health.

 

May 6, 2013

Pregnant women should not use migraine-prevention medications containing valproate sodium due to a higher risk of decreased IQ scores in children, the Food and Drug Administration warned.

SILVER SPRING, Md. — Pregnant women should not use migraine-prevention medications containing valproate sodium due to a higher risk of decreased IQ scores in children, the Food and Drug Administration warned Monday.

In addition to being used to prevent migraines, valproate drugs are used for treating epilepsy and bipolar disorder and include related drugs such as divalproex sodium and valproic acid. Most are available in generic form as well as under brand names like AbbVie's Depacon and Depakote and others.

March 8, 2013

With private label across analgesics up an estimated 11.3% to $1.7 billion, retailers are going to need to make some tough decisions as two internal analgesic powerhouses — McNeil's Tylenol and Novartis' Excedrin — make their way back onto market after respective recalls.

With private label across analgesics up an estimated 11.3% to $1.7 billion, retailers are going to need to make some tough decisions as two internal analgesic powerhouses — McNeil's Tylenol and Novartis' Excedrin — make their way back onto market after respective recalls. Within internal analgesic tablets, sales of store brand equivalents were up 15% off of a 2011 base of around $1.2 billion. The branded competition also were benefactors — both Pfizer's Advil and Bayer's Aleve generated more than $50 million in incremental sales on top of 2011 sales.

February 5, 2013

GelStat Corporation announced that it has retained List Services Corporation to manage all branding and marketing efforts for GelStat and its products, GelStat Migraine and GelStat Sleep.

PALM CITY, Fla. — GelStat Corporation on Monday announced that it has retained List Services Corp. to manage all branding and marketing efforts for GelStat Corporation and its products, GelStat Migraine and GelStat Sleep. LSC is a direct marketing agency that has evolved from a list management and brokerage house into a full service solution.

January 3, 2013

Par Pharmaceutical Cos. has started shipping two formulations of a generic drug for treating migraines, the company said.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has started shipping two formulations of a generic drug for treating migraines, the company said.

Par announced the shipment of rizatriptan benzoate tablets and rizatriptan benzoate orally disintegrating tablets in the 5-mg and 10-mg strengths. The drug is used to treat acute migraine with or without aura in patients ages 6 years and older.

The drug has sales of about $653 million per year, according to IMS Health.

November 27, 2012

Akeso Health Sciences on Tuesday announced the availability of MigreLief Triple Therapy with Puracol, a nonprescription, comprehensive supplement formulated to maintain normal cerebrovascular function by addressing the underlying nutritional deficiencies and imbalances common to many migraine sufferers.

LOS ANGELES — Akeso Health Sciences on Tuesday announced the availability of MigreLief Triple Therapy with Puracol, a nonprescription, comprehensive supplement formulated to maintain normal cerebrovascular function by addressing the underlying nutritional deficiencies and imbalances common to many migraine sufferers.   

November 14, 2012

Novartis Consumer Health on Wednesday announced the development of a convenient migraine trigger tracking tool, My Migraine Triggers App, with a neurologist.

PARSIPPANY, N.J. — Novartis Consumer Health on Wednesday announced the development of a convenient migraine trigger tracking tool, My Migraine Triggers App, with a neurologist. The company also partnered with Jordin Sparks, singer, actress and Broadway performer, and Keri Peterson, an internist at Lenox Hill Hospital, on the launch of "Managing Migraines: Know Your Triggers. Know Your Treatment," an educational campaign to raise awareness around the importance of knowing individual migraine triggers. 

September 24, 2012

Prestige Brands on Monday announced the launch of Goody's in a caplet format.

IRVINGTON, N.Y. — Prestige Brands on Monday announced the launch of Goody's in a caplet format. The pain reliever had long been sold as a powder. 

September 4, 2012

Bayer HealthCare's Consumer Care Division on Tuesday introduced Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms like nausea, phonophobia (sound sensitivity) and photophobia (light sensitivity) through a formulation of aspirin, acetaminophen and caffeine.

MORRISTOWN, N.J. — Bayer HealthCare's Consumer Care Division on Tuesday introduced Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms like nausea, phonophobia (sound sensitivity) and photophobia (light sensitivity) through a formulation of aspirin, acetaminophen and caffeine.

May 18, 2012

Solantic, an operator of urgent care centers in Florida, is changing its name to CareSpot Express Healthcare to represent a new brand and new vision for the company.

NASHVILLE, Tenn. and JACKSONVILLE, Fla. — Solantic, an operator of urgent care centers in Florida, is changing its name to CareSpot Express Healthcare to represent a new brand and new vision for the company.

February 1, 2012

Impax Pharmaceuticals said Wednesday that it obtained exclusive U.S. commercial rights to a drug for migraine headaches made by AstraZeneca.

HAYWARD, Calif. — Impax Pharmaceuticals said Wednesday that it obtained exclusive U.S. commercial rights to a drug for migraine headaches made by AstraZeneca.

January 25, 2012

The National Advertising Review Board on Tuesday recommended that Novartis Consumer Health discontinue advertising claims that the company’s Excedrin Extra Strength product starts relieving headache pain faster than Advil.

NEW YORK — The National Advertising Review Board on Tuesday recommended that Novartis Consumer Health discontinue advertising claims that the company’s Excedrin Extra Strength product starts relieving headache pain faster than Advil.

The claims at issue were initially challenged before the National Advertising Division of the Council of Better Business Bureaus by Pfizer Consumer Healthcare, makers of Advil.

August 17, 2011

Mylan announced Wednesday that it filed with the Food and Drug Administration for approval of a generic version of a drug for migraine headaches made by Endo Pharmaceuticals.

PITTSBURGH — Mylan announced Wednesday that it filed with the Food and Drug Administration for approval of a generic version of a drug for migraine headaches made by Endo Pharmaceuticals.

Mylan said it was the first to file for approval of a generic version of Frova (frovatriptan succinate EQ) tablets in the 2.5-mg strength. In response, Endo has filed a patent infringement lawsuit against Mylan in response to the filing.

Frova had sales of $68.2 million during the 12-month period ended in June, according to IMS Health.

August 10, 2011

GelStat Corp. on Tuesday announced it has retained Scarsdale Equities as its financial adviser to explore various strategic alternatives.

PALM CITY, Fla. — GelStat Corp. on Tuesday announced it has retained Scarsdale Equities as its financial adviser to explore various strategic alternatives.

"The company is in the final stages of its restructuring that began in 2008 and the timing is optimal for us to fully analyze all of our strategic options," stated Gerald Kieft, CEO of GelStat Corp.

July 12, 2011

PuraMed BioScience on Monday announced that headache researcher Roger Cady will be exhibiting a poster presentation of his independent clinical study of PuraMed's nonprescription migraine medication LipiGesic-M at the 2011 Headache Update Conference being held in Orlando, Fla., July 14 to 17.

SCHOFIELD, Wis. — PuraMed BioScience on Monday announced that headache researcher Roger Cady will be exhibiting a poster presentation of his independent clinical study of PuraMed's nonprescription migraine medication LipiGesic-M at the 2011 Headache Update Conference being held in Orlando, Fla., July 14 to 17.

February 3, 2011

US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.

LOUISVILLE, Ky. — US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.

The company announced the launch of Alsuma auto-injector (sumatriptan), which injects the drug sumatriptan under the skin via a single-use, prefilled auto injector. The company is selling the drug under a licensing agreement from King Pharmaceuticals.

January 31, 2011

Anticipating regulatory approval, MAP Pharmaceuticals and Allergan will collaborate to promote a drug for treating acute migraine to physicians.

IRVINE, Calif. — Anticipating regulatory approval, MAP Pharmaceuticals and Allergan will collaborate to promote a drug for treating acute migraine to physicians.

The two companies announced the collaboration Monday for Levadex (dihydroergotamine), an inhaled drug. Phase-3 trials for the drug are finished, and MAP plans to submit an approval application for the drug to the Food and Drug Administration in the first half of this year.

October 17, 2010

A popular beauty treatment has won approval as a medical treatment as well....

SILVER SPRING, Md. A popular beauty treatment has won approval as a medical treatment as well.

 

The Food and Drug Administration announced Friday the approval of Allergan’s Botox (onabotulinumtoxinA) for preventing headaches in adult patients with chronic migraine.

 

 

August 26, 2010

Topical BioMedics on Thursday announced that its Topricin pain relief and healing cream has been...

RHINEBECK, N.Y. Topical BioMedics on Thursday announced that its Topricin pain relief and healing cream has been awarded a patent as a treatment of pain associated with fibromyalgia. A Food and Drug Administration-regulated topical biomedicine, Topricin was introduced by the company in 1994, the company stated.

 

August 1, 2010

The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals...

SCHAUMBURG, Ill. The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals for treating migraine attacks, Sagent said Monday.

 

The FDA approved Sagent’s sumatriptan succinate injection in the 6 mg per 0.5 milliliter strength. The drug is used to treat acute migraine attacks and cluster headache episodes.

 

 

Sumatriptan is a generic version of GlaxoSmithKline’s Imitrex. Injectable sumatriptan had $22 million in sales in 2009, according to IMS Health.

July 13, 2010

Teva Pharmaceuticals has launched a drug for treating migraine headaches, the generic drug maker said....

NORTH WALES, Pa. Teva Pharmaceuticals has launched a drug for treating migraine headaches, the generic drug maker said.

 

Teva announced the launch of naratriptan tablets in the 1 mg and 2.5-mg strengths. The tablets are a generic version of GlaxoSmithKline’s Amerge. The drug is used to treat acute migraine attacks in adults with or without visual disturbances preceding the attacks known as aura.

 

 

July 11, 2010

Sandoz has launched a generic drug for treating migraine headaches, the generics arm of Swiss...

PRINCETON, N.J. Sandoz has launched a generic drug for treating migraine headaches, the generics arm of Swiss drug maker Novartis said Monday.

 

Sandoz launched naratriptan hydrochloride tablets in the 2.5-mg strength, a generic version of GlaxoSmithKline’s Amerge. The tablets are used for treating acute migraine attacks in adults with or without visual disturbances that occur before the onset of the headache, also known as aura. Studies have indicated that around 12% of Americans have migraine attacks.

 

 

July 8, 2010

Roxane Labs announced Thursday the launch of two new generic drugs....

COLUMBUS, Ohio Roxane Labs announced Thursday the launch of two new generic drugs.

 

The Columbus, Ohio-based generics subsidiary of German drug maker Boehringer Ingelheim, launched naratriptan tablets in the 1-mg and 2.5-mg strengths, and anastrozole tablets in the 1-mg strength.

 

 

June 7, 2010

Nautilus Neurosciences has launched a new treatment for migraines, the drug maker said Tuesday....